Both MindMed and Atai Life Sciences look set to trade on the Nasdaq, presenting a trio of psychedelic companies on one of the world’s most prestigious stock exchanges. MindMed today announced their application to uplist to the Nasdaq was a success. As such, the company expects to commence trading on Tuesday April 27th, under symbol MNMD. Atai’s preliminary prospectus also published this week…


Previous articlePTSF56 – Data vs. Spin, with Tim Cools of Psychedelic Experience
Next articleRed Light Holland and Headland West Indies Lead #SVGStrong, a Relief Effort in St. Vincent and the Grenadines